Viking Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Viking Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-2,034.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
+21%Cash, after subtracting all debt, equals 21% of its market value (net cash).
Higher than 64% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Viking Therapeutics, Inc. made a loss over the last year. Viking Therapeutics, Inc. owes $0.22 for every $1 it owns. Viking Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossViking Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.04The share price is 8.04 times Viking Therapeutics, Inc.'s book value per share, higher than 82% of Healthcare companies in United States.
Market cap
$3.3 BThe total market value of all of Viking Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 80% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$408 MWhat Viking Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.21Net worth divided by the number of shares. The share price of $25.83 is 8.0 times this, which is the P/B above.
Return on equity (ROE)
-88.8%Viking Therapeutics, Inc. lost 88.8% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
Owes vs Owns
0.22×Viking Therapeutics, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Dividend yield
NoneViking Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossViking Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashViking Therapeutics, Inc. held $706 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Viking Therapeutics, Inc.: $3.3 B ÷ $408 M (30 Jun 2026) = 8.0.
What is Viking Therapeutics, Inc.'s return on equity?
Viking Therapeutics, Inc. lost 88.8% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
How much does Viking Therapeutics, Inc. owe compared with what it owns?
Viking Therapeutics, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Does Viking Therapeutics, Inc. pay a dividend?
No. Viking Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.